MedTrace Logo

Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）

NCT06997913 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-05-31

No results posted yet for this study

Summary

The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can improve patients' recurrence-free survival. The primary study endpoint of this prospective study is the 2-year recurrence-free survival.

Conditions

  • Lymph Node Metastasis
  • Neurovascular Invasion
  • Pathology Showed R1 Resection

Interventions

COMBINATION_PRODUCT

Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）

The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can improve patients' recurrence-free survival. The primary study endpoint of this prospective study is the 2-year recurrence-free survival.

Sponsors & Collaborators

  • Hengchao Yu

    lead OTHER

Principal Investigators

  • Lin Wang Professor.Wang, Doctor of Medicine(M.D.) · Department of Hepatobiliary Surgery, the First Affiliated Hospital of Air Force Military Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-15
Primary Completion
2026-05-30
Completion
2027-12-30

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06997913 on ClinicalTrials.gov